Anuh Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE489G01022
  • NSEID: ANUHPHR
  • BSEID: 506260
INR
78.66
-0.91 (-1.14%)
BSENSE

Jun 18

BSE+NSE Vol: 47.56 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Mar'16
Mar'15
Net Sales
68.41
70.42
Other Operating Income
1.73
1.00
Total Operating income
70.14
71.42
Raw Material Cost
42.33
48.21
Purchase of Finished goods
2.28
1.15
(Increase) / Decrease In Stocks
9.08
7.47
Employee Cost
1.60
1.45
Power Cost
0.48
0.77
Manufacturing Expenses
7.99
4.51
Selling and Distribution Expenses
0.00
0.00
Other Expenses
0.11
0.58
Total Expenditure (Excl Depreciation)
63.86
64.15
Operating Profit (PBDIT) excl Other Income
6.28
7.27
Other Income
1.29
1.48
Operating Profit (PBDIT)
7.57
8.75
Interest
0.03
0.03
Exceptional Items
0.00
0.00
Gross Profit (PBDT)
7.54
8.72
Depreciation
0.57
1.87
Profit Before Tax
6.97
6.85
Tax
1.83
1.87
Provisions and contingencies
0.00
0.00
Profit After Tax
5.14
4.98
Extraordinary Items
0.00
0.00
Prior Period Expenses
0.00
0.00
Other Adjustments
0.00
0.00
Net Profit
5.14
4.98
Share in Profit of Associates
0.00
0.00
Minority Interest
0.00
0.00
Other related items
0.00
0.00
Consolidated Net Profit
0.00
0.00
Equity Capital
12.53
4.18
Face Value
5.0
5.0
Reserves
0.00
0.00
Earnings per share (EPS)
2.05
1.99
Diluted Earnings per share
2.05
5.97
Operating Profit Margin (Excl OI)
8.95%
10.18%
Gross Profit Margin
10.75%
12.21%
PAT Margin
7.32%
6.98%
Public Share Holdings (%)
0.0%
35.01%
Pledged Promotor Holding (%)
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is 2.51% vs 6.08% in Dec 2025

stock-summary

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -13.16% vs 76.74% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 3.97% vs 61.08% in Dec 2025

stock-summary

Interest

QoQ Growth in quarter ended Mar 2026 is 37.50% vs 0.00% in Dec 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Anuh Pharma With
Markets Mojo
Figures in Cr
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
68.41
50.89
17.52
34.43%
Other Operating Income
1.73
0.00
1.73
Total Operating income
70.14
50.89
19.25
37.83%
Raw Material Cost
42.33
52.78
-10.45
-19.80%
Purchase of Finished goods
2.28
0.00
2.28
(Increase) / Decrease In Stocks
9.08
-24.93
34.01
136.42%
Employee Cost
1.60
1.54
0.06
3.90%
Power Cost
0.48
0.00
0.48
Manufacturing Expenses
7.99
0.00
7.99
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
0.11
6.21
-6.10
-98.23%
Total Expenditure (Excl Depreciation)
63.86
35.60
28.26
79.38%
Operating Profit (PBDIT) excl Other Income
6.28
15.29
-9.01
-58.93%
Other Income
1.29
0.01
1.28
12,800.00%
Operating Profit (PBDIT)
7.57
15.30
-7.73
-50.52%
Interest
0.03
0.57
-0.54
-94.74%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
7.54
14.73
-7.19
-48.81%
Depreciation
0.57
0.29
0.28
96.55%
Profit Before Tax
6.97
14.44
-7.47
-51.73%
Tax
1.83
3.37
-1.54
-45.70%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
5.14
11.07
-5.93
-53.57%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
5.14
11.07
-5.93
-53.57%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
0.00
0.57
-0.57
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
0.00
10.50
-10.50
-100.00%
Equity Capital
12.53
53.15
-40.62
-76.43%
Face Value
5.00
10.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
2.05
0.20
1.85
925.00%
Diluted Earnings per share
2.05
0.23
1.82
791.30%
Operating Profit Margin (Excl OI)
8.95%
30.05%
0.00
-21.10%
Gross Profit Margin
10.75%
28.94%
0.00
-18.19%
PAT Margin
7.32%
21.75%
0.00
-14.43%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 202.12 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 2.51% vs 6.08% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 2.01% vs 20.90% in Mar 2025

Quarterly - Standalone Net Profit
Standalone Net Profit 11.68 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is -13.16% vs 76.74% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -6.26% vs -18.88% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 19.88 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 3.97% vs 61.08% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 6.42% vs -2.86% in Mar 2025

Quarterly - Interest
Interest 0.11 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 37.50% vs 0.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 266.67% vs -70.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 9.84%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."